Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

Table 3 Comparison of immune indicators (mean ± SD)

Group	CD3+ (%)		CD4+ (%)		CD8+ (%)		CD4+/CD8+ (%)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 50)	54.65 ± 4.32	58.16 ± 4.83	33.54 ± 3.98	38.09 ± 4.62	27.89 ± 3.65	25.16 ± 3.84	1.28 ± 0.51	1.63 ± 0.27
Observation group (n = 50)	54.02 ± 4.54	61.98 ± 5.16a	32.97 ± 4.08	40.65 ± 4.84a	28.06 ± 3.94	21.55 ± 3.17a	1.24 ± 0.49	1.92 ± 0.35a
t value	0.711	3.821	0.708	2.708	0.222	5.126	0.402	4.632
P value	0.478	< 0.001	0.481	0.008	0.825	< 0.001	0.688	< 0.001

^aP < 0.05 compared with the control group.